These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 27926778

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H.
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [Abstract] [Full Text] [Related]

  • 6. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
    Park S, Koh J, Kim DW, Kim M, Keam B, Kim TM, Jeon YK, Chung DH, Heo DS.
    Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
    [Abstract] [Full Text] [Related]

  • 7. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
    Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R.
    Cancer Biol Ther; 2011 Jul 01; 12(1):9-46. PubMed ID: 21543897
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas.
    Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Ignatius Ou SH, Kim KM.
    Mod Pathol; 2013 Dec 01; 26(12):1632-41. PubMed ID: 23807774
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
    Rossi E, Villanacci V, Danesino C, Donato F, Nascimbeni R, Bassotti G.
    Rev Esp Enferm Dig; 2011 Dec 01; 103(12):632-9. PubMed ID: 22217347
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS, Gebauer F, Krämer M, Alakus H, Berlth F, Chon SH, Schiffmann L, Zander T, Büttner R, Hölscher AH, Bruns CJ, Quaas A, Loeser H.
    BMC Cancer; 2019 Jan 08; 19(1):38. PubMed ID: 30621632
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J, Guo L, Liu X, Li W, Ying J.
    Oncotarget; 2017 Feb 07; 8(6):10264-10273. PubMed ID: 28052014
    [Abstract] [Full Text] [Related]

  • 15. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ.
    J Clin Oncol; 2011 Dec 20; 29(36):4803-10. PubMed ID: 22042947
    [Abstract] [Full Text] [Related]

  • 16. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
    Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.
    Ann Oncol; 2013 Jul 20; 24(7):1754-1761. PubMed ID: 23524864
    [Abstract] [Full Text] [Related]

  • 17. MET expression and amplification in patients with localized gastric cancer.
    Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA.
    Cancer Epidemiol Biomarkers Prev; 2011 May 20; 20(5):1021-7. PubMed ID: 21393565
    [Abstract] [Full Text] [Related]

  • 18. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
    Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, Rha SY, Chung HC.
    J Surg Oncol; 2018 Jun 20; 117(8):1679-1686. PubMed ID: 29790169
    [Abstract] [Full Text] [Related]

  • 19. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G, Gasparini P, Conte D, Fabbri A, Perrone F, Tamborini E, Pupa SM, Ciravolo V, Caserini R, Rossi G, Cavazza A, Papotti M, Nakatani Y, Maisonneuve P, Pastorino U, Sozzi G.
    J Thorac Oncol; 2016 May 20; 11(5):718-728. PubMed ID: 26804638
    [Abstract] [Full Text] [Related]

  • 20. Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma.
    Kwon D, Yun JY, Keam B, Kim YT, Jeon YK.
    World J Gastroenterol; 2016 Nov 28; 22(44):9803-9812. PubMed ID: 27956804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.